0001415889-24-010777.txt : 20240412 0001415889-24-010777.hdr.sgml : 20240412 20240412182349 ACCESSION NUMBER: 0001415889-24-010777 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240410 FILED AS OF DATE: 20240412 DATE AS OF CHANGE: 20240412 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ballal Rahul D. CENTRAL INDEX KEY: 0001805097 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39247 FILM NUMBER: 24842701 MAIL ADDRESS: STREET 1: 116 HUNTINGTON AVENUE STREET 2: 6TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Enliven Therapeutics, Inc. CENTRAL INDEX KEY: 0001672619 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 811523849 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6200 LOOKOUT ROAD CITY: BOULDER STATE: CO ZIP: 80301 BUSINESS PHONE: 720-647-8519 MAIL ADDRESS: STREET 1: 6200 LOOKOUT ROAD CITY: BOULDER STATE: CO ZIP: 80301 FORMER COMPANY: FORMER CONFORMED NAME: IMARA Inc. DATE OF NAME CHANGE: 20160419 4 1 form4-04122024_100442.xml X0508 4 2024-04-10 0001672619 Enliven Therapeutics, Inc. ELVN 0001805097 Ballal Rahul D. C/O ENLIVEN THERAPEUTICS, INC. 6200 LOOKOUT ROAD BOULDER CO 80301 true false false false 1 Common Stock 2024-04-10 4 M 0 13600 12.60 A 35941 D Common Stock 2024-04-10 4 S 0 13600 21.0106 D 22341 D Common Stock 2024-04-11 4 M 0 48820 12.60 A 71161 D Common Stock 2024-04-11 4 M 0 4580 19.68 A 75741 D Common Stock 2024-04-11 4 S 0 30300 23.1361 D 45441 D Common Stock 2024-04-11 4 S 0 20032 24.9951 D 25409 D Common Stock 2024-04-11 4 S 0 3068 25.2094 D 22341 D Stock Option (right to buy) 12.60 2024-04-10 4 M 0 13600 0 D 2028-10-19 Common Stock 13600 48820 D Stock Option (right to buy) 12.60 2024-04-11 4 M 0 48820 0 D 2028-10-19 Common Stock 48820 0 D Stock Option (right to buy) 19.68 2024-04-11 4 M 0 4580 0 D 2029-05-16 Common Stock 4580 75742 D The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023. This transaction was executed in multiple trades at prices ranging from $21.00 to $21.16. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. This transaction was executed in multiple trades at prices ranging from $23.00 to $23.94. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. This transaction was executed in multiple trades at prices ranging from $24.015 to $25.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. This transaction was executed in multiple trades at prices ranging from $25.02 to $25.485. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. All of the shares subject to this option are fully vested and exercisable as of the date hereof. /s/ Ben Hohl, by power of attorney 2024-04-12